Published in Women's Health Weekly, October 2nd, 1995
These results suggested that to monitor the efficacy of AZT therapy during pregnancy, it may be necessary to measure both the amount of HIV in the mother, which has been shown previously to be a major determinant of transmission, and whether resistance to AZT is present. They also demonstrated that AZT therapy alone may not be effective in preventing transmission from some women; in these pregnant women,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.